MedTrace Logo

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

NCT05109442 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2025-08-20

Study results available
· View outcomes & findings →

Summary

AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

AFM24

intravenous infusion

DRUG

Atezolizumab 840 MG in 14 ML Injection

intravenous infusion

Sponsors & Collaborators

  • Affimed GmbH

    lead INDUSTRY

Principal Investigators

  • Daniela Morales-Espinosa, MD · Affimed GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2025-03-06
Completion
2025-06-11
FDA Drug
Yes

Countries

  • United States
  • Poland
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05109442 on ClinicalTrials.gov